The company identified 7 studies from the clinical evidence search which incorporated an economic analysis. However, it was unable to draw any firm conclusions from these studies. The external ...

LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT announced today that the Spectra Optia system mononuclear cell (MNC) collection protocol is now cleared by the U.S. Food and Drug Administration (FDA) and ...

The Spectra Optia(R) Apheresis System from Terumo Blood and Cell Technologies in combination with UVA PIT system can now be used to provide extracorporeal photopheresis immunotherapy The company is ...

Terumo's Spectra Optia® Apheresis System Terumo's Spectra Optia® Apheresis System LAKEWOOD, Colo., U.S., and SANTA ROSA, Calif., U.S., July 27, 2022 (GLOBE NEWSWIRE) -- Acute kidney injury (AKI) and ...

Terumo Blood and Cell Technologies presents data on collection efficiency process with Spectra Optia(R) Apheresis System at major conferences Lakewood, Colorado, US, May 25, 2023 – Terumo Blood and ...

LAKEWOOD, Colorado, April 6, 2017 /PRNewswire/ -- Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that the Spectra Optia ® Apheresis ...

The National Institute for Health and Care Excellence (NICE) in the UK approved a new treatment for sickle cell disease. The National Health Service (NHS) watchdog says the new treatment could save ...

[Updated] The Bermuda Hospitals Board has launched service of the Spectra Optia therapeutic apheresis machine, with the BHB saying that Bermuda’s sickle cell patients are now better served thanks to ...

LONDON, Feb. 14, 2024 /PRNewswire/ -- Children, young people, and adults across England suffering from sickle cell disease will soon benefit from better care closer to where they live, following the ...

The Spectra Optia Apheresis System (Terumo BCT) is an apheresis and cell collection platform which can be used in the treatment of sickle cell disease. The purpose of this evaluation is to assess the ...

LONDON, Feb. 14, 2024 /PRNewswire/ -- Children, young people, and adults across England suffering from sickle cell disease will soon benefit from better care closer to where they live, following the ...